Redeye comments on yesterday’s announcement that OncoZenge’s rights issue has concluded, with combin...
Bittium signed a two-year Memorandum of Understanding (MoU) with Safran Electronics & Defense to dev...
Redeye comments on SSH Communications Security's profit warning issued yesterday evening, in which t...
Bittium announced that it has signed a MoU with French Safran, which provides navigation systems, fl...
* Q3e: 13.5% organic sales growth, 8% EBITA margin * H2 faces fewer GM headwinds * Trading at 9x '27...
Redeye comments on Neem’s Hill’s business update. We are positive on the continued development of th...
Redeye provides an updated take on Lytix’ investment case.
SynAct Pharma has received useful external validation for lead asset resomelagon’s dengue programme,...
Alligator Bioscience obtained a preliminary subscription rate of 17%.
BONESUPPORT announced this morning that it has submitted the complete additional data package reques...
Efter ett par tuffa år med kraftiga nedskärningar från regionerna syns nu tecken på en vändning för ...
Redeye comments on NYORDA's announcement of the full market launch of EMNA AI, the group's fifth bra...
Redeye updates its base case on Oncopeptides' announcement that CHMP has adopted a positive opinion ...
Topic: H1 confirms the pivot from a broad lifestyle group to a focused membership and travel- servic...
Redeye initiates coverage of AddLife, a specialized European serial acquirer operating across Medtec...
Mangold inleder bevakning av fastighetsbolaget Episurf Medical (Episurf).
BeammWave's third-generation RF chip is alive. The bring-up removes the largest technical risk in th...
Smartbroker Holding AG delivered a marked improvement in operating performance in the ...
Mendus has initiated the Phase Ib DIVA trial, marking the first clinical evaluation of vididencel in...
